Author Correction: Inhibitory effects of dopamine receptor D1 agonist on mammary tumor and bone metastasis

Author Correction: Inhibitory effects of dopamine receptor D1 agonist on mammary tumor and bone metastasis

Bibliographic Details
Main Authors:	Kazumasa Minami, Shengzhi Liu, Yang Liu, Andy Chen, Qiaoqiao Wan, Sungsoo Na, Bai-Yan Li, Nariaki Matsuura, Masahiko Koizumi, Yukun Yin, Liangying Gan, Aihua Xu, Jiliang Li, Harikrishna Nakshatri, Hiroki Yokota
Format:	Article
Language:	English
Published:	Nature Portfolio 2022-11-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-022-22386-8

Similar Items

Mechanical tibial loading remotely suppresses brain tumors by dopamine-mediated downregulation of CCN4
by: Yao Fan, et al.
Published: (2021-05-01)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
by: Xiaoshuang Liu, et al.
Published: (2019-01-01)

Dopamine Agonists for Pituitary Adenomas
by: Odelia Cooper, et al.
Published: (2018-08-01)

Aged Breast Extracellular Matrix Drives Mammary Epithelial Cells to an Invasive and Cancer‐Like Phenotype
by: Gokhan Bahcecioglu, et al.
Published: (2021-11-01)

The outcome of macroprolactinomas resistant to dopamine agonists
by: Coculescu, M, et al.
Published: (2005)

Impulse control disorders and dopamine agonists
by: D. Martins, et al.
Published: (2021-04-01)

Experience with Dopamine Agonists in the Treatment of Prolactinomas
by: Nadiya Barabash, et al.
Published: (2022-11-01)

Reduction in Migratory Phenotype in a Metastasized Breast Cancer Cell Line via Downregulation of S100A4 and GRM3
by: Andy Chen, et al.
Published: (2017-06-01)

Systemic Actions of Breast Cancer Facilitate Functional Limitations
by: Ruizhong Wang, et al.
Published: (2020-01-01)

Distinctive subcellular inhibition of cytokine-induced SRC by salubrinal and fluid flow.
by: Qiaoqiao Wan, et al.
Published: (2014-01-01)

Skeletal muscle-specific overexpression of miR-486 limits mammary tumor-induced skeletal muscle functional limitations
by: Ruizhong Wang, et al.
Published: (2022-06-01)

Skeletal muscle-specific overexpression of miR-486 limits mammary tumor-induced skeletal muscle functional limitations
by: Ruizhong Wang, et al.
Published: (2022-09-01)

Aging‐associated skeletal muscle defects in HER2/Neu transgenic mammary tumour model
by: Ruizhong Wang, et al.
Published: (2021-01-01)

Dopamine dysregulation syndrome after prescription of dopamine agonists: a case report
by: M.L. Costa, et al.
Published: (2022-06-01)

Tracking the Progression of Triple Negative Mammary Tumors over Time by Chemometric Analysis of Urinary Volatile Organic Compounds
by: Mark Woollam, et al.
Published: (2021-03-01)

Dopamine Agonist Therapy in Advanced Parkinson’s Disease
by: Heinz Reichmann
Published: (2009-05-01)

Predictors of dopamine agonist resistance in prolactinoma patients
by: Elle Vermeulen, et al.
Published: (2020-05-01)

Chemometric Analysis of Urinary Volatile Organic Compounds to Monitor the Efficacy of Pitavastatin Treatments on Mammary Tumor Progression over Time
by: Paul Grocki, et al.
Published: (2022-07-01)

Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists
by: Vladimir M. Pogorelov, et al.
Published: (2023-11-01)

Dopamine agonist and tamoxifen combination therapy for a prolactin-secreting pituitary tumor resistant to dopamine agonist monotherapy: Case report and review
by: Zachary K. Christian, et al.
Published: (2020-09-01)

Dopamine agonist monotherapy utilization in patients with Parkinson’s disease
by: Monica Frazer, et al.
Published: (2023-01-01)

The efficacy of the dopamine agonist Rotigotine in the treatment of Parkinson's disease
by: Marina Romanovna Nodel
Published: (2013-11-01)

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
by: Claudia Pivonello, et al.
Published: (2022-01-01)

The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
by: Shuman Wang, et al.
Published: (2021-11-01)

Impulse control and related behavioral disorders (ICRD) in Idiopathic Parkinson’s Disease treated with different dopamine agonists in Hong Kong: Is any dopamine agonist better?
by: Hiu Fung Wu, et al.
Published: (2024-01-01)

Acquisition, processing, and single-cell analysis of normal human breast tissues from a biobank
by: Poornima Bhat-Nakshatri, et al.
Published: (2022-03-01)

Dopamine agonists and risk: Impulse control disorders in Parkinson's; Disease
by: Voon, V, et al.
Published: (2011)

The effects of the dopamine agonist rotigotine on hemispatial neglect following stroke.
by: Gorgoraptis, N, et al.
Published: (2012)

Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists?
by: Turner, H, et al.
Published: (1999)

The effects of the dopamine agonist rotigotine on hemispatial neglect following stroke
by: Gorgoraptis, N, et al.
Published: (2012)

The rapid diagnosis of sensitivity or resistance to dopamine agonists with depot bromocriptine.
by: Grossman, A, et al.
Published: (1987)

Dopamine agonists and risk: impulse control disorders in Parkinson's disease.
by: Voon, V, et al.
Published: (2011)

The effect of dopamine agonist therapy on large functionless pituitary tumours.
by: Grossman, A, et al.
Published: (1985)

Dopamine receptor agonists: standard and non-standard applications in medicine
by: E. E. Vasenina, et al.
Published: (2022-03-01)

Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?
by: Pavel Mohr, et al.
Published: (2022-01-01)

Irreversible extreme freezing of gait after dopamine agonist withdrawal
by: Mehri Salari, et al.
Published: (2021-08-01)

Metabolic effects of prolactin and the role of dopamine agonists: A review
by: Polly Kirsch, et al.
Published: (2022-09-01)

Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
by: Ronan Talty, et al.
Published: (2022-08-01)

Could Dopamine Agonists Aid in Drug Development for Anorexia Nervosa?
by: Guido eFrank
Published: (2014-11-01)

MORPHINE-INDUCED HYPERACTIVITY IN RATS IS ENHANCED BY THE SELECTIVE D2 DOPAMINE ANTAGONIST RACLOPRIDE AND BLOCKED BY DOPAMINE AGONISTS
by: Oneill, M, et al.
Published: (1990)